German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors

德国生物医学研究所X与日本制药公司Daiichi Sankyo建立了新的合作伙伴关系，以推动用于治疗实体瘤的双特异性和多特异性生物制剂的开发

HEIDELBERG, Germany, January 14, 2025 / Biotech Newswire / --

德国海德堡，2025年1月14日/生物技术通讯社/--

BioMed X

生物医学X

, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with

总部位于德国海德堡的一家独立生物医学研究所今天宣布与

Daiichi Sankyo Co., Ltd

大一三九有限公司

., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new project, entitled “

，一家总部位于日本的全球性制药公司。这项合作标志着一项前沿举措的开始，该举措旨在探索使用多特异性生物制剂进行癌症治疗的创新方法。新项目名为“

New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics

多特异性生物制剂靶向实体瘤的新策略

(MTT; Multi-Specific Targeting of Tumors)”, will be hosted at the BioMed X Institute in Heidelberg.

（MTT；肿瘤的多特异性靶向）”将在海德堡的生物医学X研究所举办。

The goal of this partnership is to leverage the latest advances in multi-functional biologics, such as bi- and tri-specific antibodies, to develop new therapies that can engage multiple targets simultaneously within the tumor microenvironment. These next-generation therapies aim to overcome the limitations of conventional treatments by leveraging synergistic effects of different antitumor signaling pathways and mechanisms by manipulating proximity of multiple targets..

这种伙伴关系的目标是利用多功能生物制剂（如双特异性和三特异性抗体）的最新进展，开发可以在肿瘤微环境中同时参与多个靶标的新疗法。这些下一代疗法旨在通过操纵多个靶标的接近度来利用不同抗肿瘤信号传导途径和机制的协同作用来克服常规治疗的局限性。。

Call for Research Proposals

呼吁研究建议

The BioMed X Institute and Daiichi Sankyo are inviting proposals from researchers around the world to participate in this ambitious project.

生物医学X研究所和第一三共正在邀请世界各地的研究人员参与这一雄心勃勃的项目。

The MTT initiative focuses on the following key research challenges:

MTT计划重点关注以下关键研究挑战：

Researchers are encouraged to submit proposals that demonstrate originality, especially those supported by preliminary experimental data or utilizing state-of-the-art machine learning tools. The call is open to projects targeting any solid tumor indication. However, classical immune cell engagers, combination therapies, and other modalities outside peptides or proteins (e.g., small molecules, nucleic acids, gene or cell therapies) are not within the scope of this project..

鼓励研究人员提交具有独创性的提案，特别是那些得到初步实验数据支持或利用最先进的机器学习工具的提案。该呼吁对针对任何实体瘤适应症的项目开放。然而，经典的免疫细胞参与者，联合疗法以及肽或蛋白质以外的其他方式（例如小分子，核酸，基因或细胞疗法）不在本项目的范围内。。

The new research team will join seven other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at .

新的研究团队将加入德国海德堡生物医学X研究所的其他七个研究小组。有兴趣加入这一新研究小组的研究人员被邀请通过BioMed X职业空间提交项目提案，以响应这一国际申请。

https://career.bio.mx/call/2025-BMX-C01

https://career.bio.mx/call/2025-BMX-C01

before March 9, 2025.

2025年3月9日前。

Christian Tidona, Founder and Managing Director of the BioMed X Institute, commented:

生物医学X研究所创始人兼董事总经理克里斯蒂安·蒂多纳评论道：

'Partnering with Daiichi Sankyo on the MTT project allows us to expand our research in oncology, focusing on next-generation biologics that can truly make a difference for cancer patients. This collaboration exemplifies our commitment to pioneering innovative therapeutic approaches.'

“与第一三共在MTT项目上的合作使我们能够扩大我们在肿瘤学方面的研究，专注于能够真正为癌症患者带来改变的下一代生物制剂。这种合作体现了我们对开创创新治疗方法的承诺。”

About

关于

BioMed X

生物医学X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents.

BioMed X是一家独立的研究机构，在德国海德堡、康涅狄格州纽黑文、康涅狄格州里奇菲尔德的XSeed实验室以及全球合作伙伴网络都设有分支机构。与我们的合作伙伴一起，我们通过将全球众包与全球最聪明的早期职业研究人才的本地孵化相结合，确定了重大的生物医学研究挑战，并提供了创造性的解决方案。

Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun..

BioMed X的每个高度多样化的研究团队都可以使用最先进的研究基础设施，并由学术界和工业界经验丰富的导师不断指导。在BioMed X，我们结合了学术界和工业界两个领域的优点，通过使生物医学研究更高效，更灵活，更有趣，实现突破性创新。。

Contact

联系人

BioMed X

生物医学X

Maria Morganti

玛丽亚 摩根蒂

Head of Marketing

+49 6221 42611 30

+49 6221 42611 30

This email address is being protected from spambots. You need JavaScript enabled to view it.

此电子邮件地址受到垃圾邮件的保护。您需要启用JavaScript才能查看它。

Keywords: International Cooperation; Academies and Institutes; Tumor Microenvironment; Antibodies, Bispecific; Neoplasms; Drug Discovery; Biomedical Research; Drug Discovery; Academies and Institutes; Germany; BioMed X Institute; Daiichi Sankyo; Cancer therapy; Solid tumors; Multi-specific biologics; Bi-specific antibodies; Tri-specific antibodies; Tumor microenvironment; Antitumor signaling pathways; Heidelberg, Germany; Research proposals; Extracellular target combinations; Intracellular target combinations; Oncology research; Christian Tidona; collaboration.

关键词：国际合作；学院和研究所；肿瘤微环境；抗体，双特异性；肿瘤；药物发现；生物医学研究；药物发现；学院和研究所；德国；生物医学X研究所；第一三共；癌症治疗；实体瘤；多特异性生物制剂；双特异性抗体；三特异性抗体；肿瘤微环境；；德国海德堡；研究建议；细胞外靶标组合；细胞内靶标组合；肿瘤学研究；克里斯蒂安·蒂多纳；协作。

Source: Biotech Newswire

资料来源：Biotech Newswire